Omega-3 Fatty Acids for Gout

The idea that omega-3 could help gout comes from two places: lab work showing EPA and DHA dampen the inflammation that urate crystals trigger, and a 2019 study of 724 people with gout. In that study, two or more servings of omega-3-rich fish in the previous 48 hours were linked to 26% lower odds of a flare, but omega-3 supplements were not linked to flare risk at all (OR 1.01).

Two small trials have since tested supplements directly. Fish oil at 6.2 g a day for 24 weeks did not lower serum urate in 40 people, and 4 g a day for 28 weeks did not reduce flares compared with placebo in 60 people starting urate-lowering therapy. Neither trial was large enough to rule out a modest effect, so the honest verdict is insufficient evidence, leaning towards no meaningful benefit.

A gout flare is an immune reaction to monosodium urate crystals in a joint. Immune cells sense the crystals through the NLRP3 inflammasome (a protein switch inside the cell) and release interleukin-1 beta, the main driver of the pain and swelling. In macrophages, EPA and DHA abolished NLRP3 activation and inhibited interleukin-1 beta release, acting through the fatty acid receptors GPR120 and GPR40, and the authors pointed to gout as a possible use.

In crystal models, DHA suppressed interleukin-1 beta release from human immune cells exposed to urate crystals, and an omega-3 drug reduced swelling by 58% (indomethacin 50%) and pain by 23% (indomethacin 41%) after urate crystals were injected into rats' knees. These are cell and animal results at controlled exposures, not evidence that capsules prevent flares in people.

In a lab test of 25 fatty acids, EPA, alpha-linolenic acid and DHA inhibited URAT1, the kidney transporter that reabsorbs urate, which in theory could raise urate excretion. The authors noted further study was needed before treating omega-3s as urate-lowering agents.

In people, that has not shown up. Serum urate did not change with 6.2 g of fish oil a day over 24 weeks. A pathway that works in a dish says nothing about whether the dose reaching a joint or kidney is enough, which is why the trials, not the mechanism, decide the verdict.

The placebo-controlled trial used 4 g of omega-3 fatty acids a day for 28 weeks, which doubled participants' red blood cell omega-3 index. The open-label trial used 6.2 g of omega-3 fish oil a day for 24 weeks. Neither trial found a benefit over its control group.

Those doses are high. FDA guidance says supplement labels should not recommend more than 2 g of EPA and DHA a day, and a meta-analysis of large trials found atrial fibrillation risk was higher with more than 1 g a day. Because no dose has a proven benefit in gout, there is no gout-specific dose to recommend.

Zhang and colleagues (2019) asked 724 people with gout online what they ate and took in the 48 hours before each flare and before flare-free periods. After adjusting for purine intake, diuretics and gout medicines, two or more servings of omega-3-rich fish were linked to lower flare risk (OR 0.74, 95% CI 0.54-0.99; P = 0.04). Omega-3 supplements, taken by 4.6% of participants, showed no link (OR 1.01, 95% CI 0.63-1.60; P = 0.98).

A US survey of 12,505 adults found a similar split: omega-3-poor seafood was associated with higher odds of gout (8.7% per unit of intake), while omega-3-rich seafood was not. Both studies are observational and cannot show that the omega-3 caused the difference. An earlier small case-control study also reported lower omega-3 levels in people with frequent gout attacks.

Stamp and colleagues (2022) randomised 40 people with gout and serum urate of 0.36 mmol/L or more to 6.2 g of omega-3 fish oil a day or no fish oil for 24 weeks, without a placebo. Urate fell by 0.021 mmol/L with fish oil and 0.006 mmol/L without, a difference that was not significant, and weight and BMI did not change. People with higher red cell omega-3 levels had fewer flares between weeks 12 and 24 (r = -0.75), but that is a correlation, not a comparison between the groups.

Abhishek and colleagues (2022) then ran a placebo-controlled feasibility trial in 60 adults starting treat-to-target urate-lowering therapy. With 4 g of omega-3 a day for 28 weeks, the number of flares (median 1 in each arm), their length (7.00 vs 7.06 days) and time to first flare (HR 0.97, 95% CI 0.50-1.86) were comparable to placebo, even though red cell omega-3 doubled in the active group.

A Cochrane review of dietary supplements for chronic gout, searching to August 2020, found only two eligible trials, neither of omega-3, and no high-quality evidence for any supplement. A 2025 systematic review of 27 trials, including n-3 fatty acids, described the findings as mixed and inconclusive.

What is missing is an adequately powered, placebo-controlled trial with flares as the main outcome. The feasibility trial was built to show such a study can be run in general practice; until it is, the evidence rests on small trials that found nothing and observational studies that point at fish rather than capsules.

Omega-3 supplements are usually well tolerated. Commonly reported side effects are mild: unpleasant taste, bad breath, heartburn, nausea, stomach discomfort, diarrhoea, headache and odorous sweat. In the 24-week gout trial, four people on 6.2 g a day had gastrointestinal effects judged definitely or probably related, and fish oil did not raise urate, weight or BMI.

The real risk at gout-trial doses is heart rhythm. In a meta-analysis of seven large cardiovascular trials (81,210 people), marine omega-3 supplements raised the risk of atrial fibrillation (HR 1.25), more so above 1 g a day (HR 1.49). Fish oil can also have antiplatelet effects at high doses, and the label for prescription omega-3 advises caution in people allergic to fish or shellfish.

No interaction with urate-lowering drugs or colchicine has been reported. In the placebo-controlled trial, participants started treat-to-target urate-lowering therapy while taking 4 g of omega-3 a day. The interactions that matter involve bleeding. The prescription omega-3 label advises periodic monitoring for anyone also taking an anticoagulant or another drug affecting coagulation, and most research finds 3-6 g a day of fish oil does not significantly change anticoagulation in people on warfarin, but INR rises have been reported, so monitoring is sensible.